Introduction of a pilot program to measure and improve the clinical care of melanoma patients in the Lower Silesian Voivodeship in Poland: a report of 20 months experience

[1]  M. Krzakowski,et al.  Ways of developing quality indicators in cancer care — opportunities, challenges and limitations for the Polish healthcare system , 2022, Oncology in Clinical Practice.

[2]  R. Matkowski,et al.  The report and analysis concerning the usefulness of basic telemedicine tools in the skin cancer diagnostic screening process during COVID-19 pandemics , 2022, Postepy dermatologii i alergologii.

[3]  A. Renshaw,et al.  Exploring the College of American Pathologists Electronic Cancer Checklists: What They Are and What They Can Do for You. , 2022, Archives of pathology & laboratory medicine.

[4]  I. Stanganelli,et al.  Proportion of Thick versus Thin Melanomas as a Benchmarking Tool , 2021, Journal of clinical medicine.

[5]  R. Matkowski,et al.  Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy , 2021, BMC Cancer.

[6]  James X. Sun,et al.  Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2) , 2021, Cancer.

[7]  L. Fallowfield,et al.  Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives , 2020, Kompass Nutrition & Dietetics.

[8]  B. Więckowska,et al.  Decreasing access to cancer diagnosis and treatment during the COVID-19 pandemic in Poland , 2020, Acta oncologica.

[9]  Lesly A. Dossett,et al.  Management of the positive sentinel lymph node in the post‐MSLT‐II era , 2020, Journal of surgical oncology.

[10]  A. Forsea.  Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities , 2020, Dermatology practical & conceptual.

[11]  Catherine Thieblemont,et al.  Impact of the COVID-19 Outbreak on the Management of Patients with Cancer , 2020, Targeted Oncology.

[12]  J. Walewski,et al.  Krajowa Sieć Onkologiczna w zakresie nowotworów litych , 2020 .

[13]  M. Bielska-Lasota,et al.  Survival in men diagnosed with prostate cancer in Poland in the years 2000 - 2014 compared to European Countries based on Concord-3. , 2020, Roczniki Panstwowego Zakladu Higieny.

[14]  M. Faries,et al.  The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes) , 2019, Annals of Surgical Oncology.

[15]  P. Grosclaude,et al.  Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study. , 2019, Breast.

[16]  A. Benson,et al.  Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies , 2019, Journal of surgical oncology.

[17]  Jan F. Nygård,et al.  Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry , 2019, Int. J. Medical Informatics.

[18]  Courtney P. Williams,et al.  Evaluating the Impact of Treatment Care Planning on Quality Measures. , 2019, Journal of oncology practice.

[19]  C. Sowada,et al.  Improving oncological care organization in Poland—The 2015 reform evaluation in the context of European experiences , 2018, The International journal of health planning and management.

[20]  V. Sondak,et al.  Microsatellitosis in Patients with Melanoma , 2018, Annals of Surgical Oncology.

[21]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[22]  A. Katalinic,et al.  Observed and expected mortality in the German skin cancer screening pilot project SCREEN , 2018, Journal of medical screening.

[23]  R. Mansel,et al.  Quality indicators in breast cancer care: An update from the EUSOMA working group. , 2017, European journal of cancer.

[24]  Johan Hansson,et al.  Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature , 2016, Clinical epidemiology.

[25]  A. Katalinic,et al.  Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013. , 2015, Deutsches Arzteblatt international.

[26]  M. Gajda,et al.  Do not let to be late: overview of reasons for melanoma delayed diagnosis. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[27]  J. Lortet-Tieulent,et al.  International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? , 2013, International journal of cancer.

[28]  M. Krzakowski,et al.  Czerniaki skóry — zasady postępowania diagnostyczno-terapeutycznego w 2013 roku , 2012 .

[29]  S. Swetter,et al.  Screening and Prevention Measures for Melanoma: Is There a Survival Advantage? , 2012, Current Oncology Reports.

[30]  L. Newcomer.  Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. , 2012, Health affairs.

[31]  K. Puttgen,et al.  Melanoma quality of life: pilot study using utility measurements. , 2011, Archives of dermatology.

[32]  Myles G Cockburn,et al.  Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.

[33]  W. Owczarek,et al.  GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT , 2017 .